Compugen (CGEN) to Release Earnings on Wednesday

Compugen (NASDAQ:CGEN) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $3.95 million for the quarter.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, May 19th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Compugen had a negative return on equity of 24.51% and a negative net margin of 51.27%. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. During the same period last year, the company posted ($0.08) earnings per share. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compugen Stock Up 2.1%

Shares of Compugen stock opened at $1.48 on Monday. Compugen has a 12-month low of $1.13 and a 12-month high of $2.66. The company has a market capitalization of $132.08 million, a price-to-earnings ratio of -9.25 and a beta of 2.61. The firm’s 50-day moving average price is $1.62 and its two-hundred day moving average price is $1.69.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.